- Home
- NMM vs NEO Comparison
NMM vs NEO Comparison
Compare NMM & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NMM | NEO |
|---|---|---|
| Founded | 2007 | 2001 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2007 | 2008 |
Fundamental Metrics
Financial Performance| Metric | NMM | NEO |
|---|---|---|
| Price | $71.10 | $9.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.14 |
| AVG Volume (30 Days) | 132.5K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 0.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.52 | $10.53 |
| Revenue Next Year | $1.73 | $9.25 |
| P/E Ratio | $7.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.37 | $4.72 |
| 52 Week High | $74.21 | $13.74 |
Technical Indicators
Market Signals| Indicator | NMM | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 74.29 | 31.22 |
| Support Level | $50.39 | $9.13 |
| Resistance Level | N/A | $11.02 |
| Average True Range (ATR) | 2.35 | 0.67 |
| MACD | 0.55 | -0.09 |
| Stochastic Oscillator | 77.89 | 19.69 |
Price Performance
Historical ComparisonAbout NMM Navios Maritime Partners LP
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.